NEW YORK, NY, USA, Feb 4, 2021 – Medidata, a Dassault Systèmes company and the global leader in creating end-to-end solutions to support the entire clinical development process, today announced its expanded partnership with Horizon Therapeutics plc (NASDAQ: HZNP). Starting in 2017 with one technology solution, Medidata will now provide a diverse suite of solutions for Horizon’s clinical research needs in multiple therapeutic areas including ophthalmology, rheumatology, and nephrology.
“We’re delighted to be a key partner to Horizon and its exceptional journey that benefits patients by advancing science and treatments,” said Tarek Sherif, co-founder and co-CEO, Medidata. “Medidata’s goal is to facilitate Horizon’s path forward using advanced analytics and technology. We’re looking forward to further supporting the company’s vision, especially as it relates to improving efficiencies and speeding the completion of clinical studies.”
Horizon will access a broad range of clinical trial solutions using the Medidata Rave Clinical Cloud, the industry’s most used platform to accelerate clinical research with a suite of applications including data capture, data management, trial planning, and trial management. In addition, Horizon will use Medidata’s Intelligent Trials product, which brings artificial intelligence (AI), partnered with advanced analytics, to bring cross-industry real-time performance metrics, predictive models, and forecasting capabilities for trial planning and execution. Intelligent Trials, provided by Acorn AI, Medidata’s data and analytics solutions, is built on the industry’s broadest clinical trial dataset, covering more than six million patients in 22,000+ clinical trials.
“Through the use of the Medidata technologies, we have been able to create a more efficient, manageable and cost-effective clinical trial process, which led us to expand this productive relationship,” said Karin Rosén, M.D., Ph.D., executive vice president research and development and chief scientific officer, at Horizon. “As our clinical needs have evolved, the Medidata platform gives us the flexibility and agility to scale and grow.”
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate evidence and insights to help pharmaceutical, biotech, medical device, and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world’s most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life Sciences.
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating ‘virtual experience twins’ of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production.
Dassault Systèmes’ 20,000 employees are bringing value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit https://www.3ds.com.